Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Van Vaerenbergh K, Van Laethem K, Van Wijngaerden E, Schmit JC, Schneider F, Ruiz L, Clotet B, Verhofstede C, Van Wanzeele F, Muyldermans G, Simons P, Stuyver L, Hermans P, Evans C, De Clercq E, Desmyter J, Vandamme AM. Van Vaerenbergh K, et al. Among authors: verhofstede c. AIDS Res Hum Retroviruses. 2000 Apr 10;16(6):529-37. doi: 10.1089/088922200308945. AIDS Res Hum Retroviruses. 2000. PMID: 10777143
Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories.
Muyldermans G, Debaisieux L, Fransen K, Marissens D, Miller K, Vaira D, Vandamme AM, Vandenbroucke AT, Verhofstede C, Schuurman R, Zissis G, Lauwers S. Muyldermans G, et al. Among authors: verhofstede c. Clin Microbiol Infect. 2000 Apr;6(4):213-7. doi: 10.1046/j.1469-0691.2000.00048.x. Clin Microbiol Infect. 2000. PMID: 11168110 Free article.
Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
Van Vaerenbergh K, Debaisieux L, De Cabooter N, Declercq C, Desmet K, Fransen K, Maes B, Marissens D, Miller K, Muyldermans G, Sprecher S, Stuyver L, Vaira D, Verhofstede C, Zissis G, Van Ranst M, De Clercq E, Desmyter J, Vandamme AM. Van Vaerenbergh K, et al. Among authors: verhofstede c. Antivir Ther. 2001 Mar;6(1):63-70. Antivir Ther. 2001. PMID: 11417763
Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Piérard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P. Ruelle J, et al. Among authors: verhofstede c. BMC Infect Dis. 2008 Feb 27;8:21. doi: 10.1186/1471-2334-8-21. BMC Infect Dis. 2008. PMID: 18304321 Free PMC article.
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, van den Heuvel A, van der Gucht B, van Ranst M, van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, van Laethem K. Vercauteren J, et al. Among authors: verhofstede c. AIDS Res Hum Retroviruses. 2008 Mar;24(3):355-62. doi: 10.1089/aid.2007.0212. AIDS Res Hum Retroviruses. 2008. PMID: 18327983
Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains.
Chalmet K, Van Wanzeele F, Demecheleer E, Dauwe K, Pelgrom J, Van Der Gucht B, Vogelaers D, Plum J, Stuyver L, Vandekerckhove L, Verhofstede C. Chalmet K, et al. Among authors: verhofstede c. Virology. 2008 Sep 30;379(2):213-22. doi: 10.1016/j.virol.2008.06.036. Epub 2008 Aug 9. Virology. 2008. PMID: 18692212 Free article.
107 results